Menin inhibitor drugs

These novel MEN1 mutations decrease the affinity of the menin inhibitor interaction, preventing drug-induced displacement of the menin MLL1 complex from chromatin and thereby abrogating

by MWM Kühn Cited by 2Quickly, other companies developed Menin inhibitors, and currently, at least four additional Menin inhibitor drugs are being assessed in

Revumenib, a drug in a new class called menin inhibitors, was developed based on research conducted at MSK. It targets certain genetic changes

Kura advancing multiple, next-generation menin inhibitor drug candidates targeting diabetes and other metabolic diseases

How menin inhibitors work Side effects: Some menin inhibitors can cause QT interval prolongation (a heart rhythm issue) and differentiation syndrome (a severe reaction to cancer treatment)1

MI-2 (Menin-MLL Inhibitor) Related Products Kinase Inhibitor Library FDA-approved Drug Library Natural Product Library Bioactive Compound Library-I

Director, Program for Drug Development in Leukemia Memorial Sloan Kettering Identify patients eligible for clinical trials investigating menin inhibitor

This work has led to the identification of novel drug targets, including DOT1 inhibitors, 1 bromodomain inhibitors, 2,3 and drugs that interfere with the Menin-MLL1 interaction. 4 Menin binds to the N-terminus of MLL-fusion proteins and is required for MLL-fusion proteins to regulate aberrant gene expression pathways via the action of DOT1L.

The menin inhibitors revumenib and ziftomenib are in close competition for a share of the acute myeloid leukaemia (AML) market.